Cellevolve Bio, INC.
🇺🇸United States
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML
Phase 2
Not yet recruiting
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- Biological: CE-VST01-JC
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Cellevolve Bio Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05541549
© Copyright 2025. All Rights Reserved by MedPath